Therapeutic hypothermia in children and adults with severe traumatic brain injury. Review Introduction Traumatic brain injury (TBI) is a major cause of death and disability in industrialized countries. In the US, for example, an estimated 1.6 million people sustain TBI every year, with about 50,000 deaths and 80,000 permanent neurological disabilities (Ghajar, 2000) . Several neuroprotective substances showing beneficial effects in animal studies, such as nimodipine, glutamate inhibitors, the competitive N-methyl-D-aspartate (NMDA) receptor antagonists, magnesium sulfate and scavenging agents have been analyzed in randomized trials in TBI patients, but none of these potential neuroprotective substances have been shown to be beneficial (Marshall 2000; Narayan et al., 2002; Maas et al., 2006; Temkin et al., 2007; . Modern therapy of TBI has improved outcome over the last 20 years, but mortality and number of patients with severe disability have remained high (Patel et al., 2005 , Rosenfeld et al., 2012 , Gerber et al., 2013 .
Increased body temperature after a brain trauma is associated with increased cytokine release and worsening of outcome (Dietrich, 1992; Thompson et al., 2003; Li and Jiang, 2012) .
Based on this and the neuroprotective effect of active hypothermia after global brain ischemia, such as after cardiac arrest (Bernard et al., 2002; Hypothermia after Cardiac arrest Study group, 2002) , after neonatal asphyxia (Shah et al., 2007) , and from case reports showing good recovery after drowning in cold water (Huckabee et al., 1990; Husby et al., 1990; Siebke et al., 1975; Wanscher et al., 2012) , great expectations have been raised about active cooling as a breakthrough in TBI patients (Polderman, 2008) . Hypothermia as a potential therapy after stroke is also under debate (Faridar et al., 2011; Lakhan and Pamplona, 2012) . Active cooling of patients with TBI was described first by Fay in 1945 and has become a major area of research during the last 2 decades. Spontaneous hypothermia, for example as a consequence of 6 6 progressive shock and inability to maintain normal temperature is, however, a poor prognostic factor (Finkelstein and Alam, 2010) .
There are several studies from the 90´s evaluating the effect of therapeutic hypothermia in severe TBI patients. Harris et al. reviewed 7 randomized controlled trials (RCT) from that period (Harris et al., 2002) and found no beneficial effects of hypothermia on outcome. Another meta-analysis of 8 randomized studies from the 90´s found no reduction in mortality from hypothermia (Henderson et al., 2003) . McIntyre et al. summarized the results of 12 studies from the 90´s (McIntyre et al., 2003) , of which only 2 of the studies were graded high-quality studies. They concluded that the scientific support for therapeutic hypothermia so far is weak.
In summary, the studies performed during the 90´s give no clear support for therapeutic hypothermia in TBI patients.
Hypothermia may still be beneficial by better planning of the studies and by optimizing the protocols as aimed at in later studies (McIntyre et al., 2003) . The purpose of this review was therefore to present and evaluate the current literature on therapeutic hypothermia in TBI patients from the year 2000 up to present. We will also present possible side effects of active hypothermia based on the specific pathophysiology of these patients. The studies analyzed included patients who suffered a severe TBI (Glasgow coma scale (GCS) score ≤ 8), and only studies with a control group that was not exposed to active cooling.
Pathophysiology in TBI
The pathophysiology of brain injury after head trauma is complex and can be characterized by the initial primary injury and the subsequent secondary injury that develops over the days following the trauma. The primary injury occurs at the moment of impact and can be focal or more diffuse (Reilly, 2001; Werner and Engelhard, 2007; Harris et al., 2009) . The focal damage is seen as contusions, contusional bleedings, lacerations, intracranial hemorrhages and local ischemia, and is an immediate effect of the trauma. The diffuse brain damage is caused by acceleration, deceleration, and/or rotational forces, and involves components such as neurons, neuronal processes, transmitter mechanisms, glial cells, and blood vessels (Reilly, 2001; Werner and Engelhard, 2007) and diffuse brain swelling (Werner and Engelhard, 2007) . It can also include diffuse axonal injury (DAI), which is a predictor of poor recovery (Greve and Zink, 2009) . Children suffer more severe edema after TBI than adults (Adelson, 2009 ).
The centre of the primary brain injury is often severely hypoxic and more or less insensitive to therapeutic interventions and most cells of these areas will die irrespective of therapy (Werner and Engelhard, 2007) , while injured cells of the surrounding areas (penumbra zones) have the potential to survive. Secondary brain injury is initiated at the moment of injury with progression over the ensuing minutes, hours, and days (Marshall, 2000; , a phenomenon termed hemorrhagic progression of a contusion (HPC) (Kurland et al., 2012) . The development of secondary brain damage is a major factor determining the patient's clinical outcome (Reilly, 2001, Greve and Zink, 2009) . A main targe is therefore to reduce the development of secondary brain damage, by improving the survival of injured but not dead cells. The pathophysiological mechanisms behind the secondary damage are not fully understood, but overall effects of biomolecular and physiological changes in the brain, including inflammatory processes with release of cytokines, cerebral edema, increased intracranial pressure (ICP), and compromised cerebral blood flow (CBF) with cerebral ischemia and apoptosis may be involved (Marshall, 2000) . A specific goal with the use of neuroprotective substances has been to reduce the 8 8 development of secondary injuries by reducing the direct toxic cell damage, and the cytotoxic brain edema. The pathophysiology, however, seems to be more complex, as neuroprotective substances tested so far in patients have failed to improve outcome. One can speculate that primary hypoxia, especially in and around contusions, may be an important additional triggering mechanism behind the pathophysiological alterations after a TBI. If so, one goal in the treatment of these patients should be to counteract the effect of hypoxia of the brain i.e by hypothermia.
TBI is supposed to increase the permeability of the tight cerebral capillaries (open the intact blood-brain barrier (BBB)). Failure of the BBB means that the normally impermeable capillaries become passively permeable to small solutes, which may cause leakage of fluid into brain tissue, a mechanism responsible for the so-called vasogenic brain edema (Grände, 2006; Chodobski et al., 2011) . Brain edema can also be an effect of swelling of brain cells, due to cell membrane damage from hypoxia or cytotoxic substances (Liang et al. 2007 ). Brain edema and intracranial hematomas will increase ICP and reduce cerebral perfusion pressure (CPP), defined as the difference between mean arterial pressure and ICP. A high ICP correlates to worse outcome in patients with TBI (Jiang et al., 2002) and is a leading cause of death after severe TBI. Low CPP values, especially combined with hypovolemia, may cause brain ischemia in areas with compromised circulation (Greve and Zink, 2009 ).
Therapeutic hypothermia in TBI
As mentioned in the Introduction hypothermia has neuroprotective effects related to global hypoxia. This initiated the view that the neuroprotective effect of active hypothermia in combination with its ICP-reducing effect might be an important therapeutic option also in TBI patients (Biswas et al., 2002; Polderman et al., 2002; Tokutomi, 2009; Hutchison et al., 2010) . Many posttraumatic adverse events at the cellular and molecular level are also highly temperature sensitive (Sahuquillo and Vilalta, 2007 ).
Brain metabolism is reduced by about 5%-7% per ºC reduction in core temperature (Finkelstein and Alam, 2010) . The ICP-reduction by active hypothermia can be explained by cerebral vasoconstriction with reduced intracranial blood volume due to reduced metabolic rate.
Reduction in brain metabolic rate may also be essential for neuroprotection by hypothermia i.e.
by causing a more favorable balance between oxygen supply and demand. Note, however, that the same decrease in metabolic rate from barbiturate treatment was not associated with improved outcome (Roberts and Sydenham, 2012) . Other protective factors may be attenuation of proinflammatory cytokines, decrease in free radicals, toxic metabolites and excitatory neurotransmittors, prevention of reperfusion injury, prevention of apoptosis, preservation of high-energy phosphates, reduced mitochondrial dysfunction, and a reduction in oxidative stress proteins and oxidative DNA damage (Dietrich, 1992; Ji, 2007; Polderman, 2008; Li and Jiang, 2012) .
Cooling technique and protocol
Cooling of the whole body (systemic cooling) has been used in all larger clinical TBI outcome studies so far. Local cooling of the brain has been discussed to reduce systemic complications such as pulmonary complications and coagulation disturbances (Finkelstein and Alam, 2010 , Shlee and Lyden, 2012 . Selective brain cooling can be obtained by a cooling cap or by cooling of the mucous membrane of the nose via a tubing system with circulating cold water inserted into the nose (Springborg et al., 2013) . Local cooling techniques have difficulty in reaching target temperatures within reasonable times (Springborg et al., 2013; Harris et al., 2012) . Liu et al. (2006) and Qiu et al. (2006) both succeeded in reducing the brain temperature to 33-35ºC using a cooling cap in combination with an ice neck strap and they reported positive results on outcome, and a lower risk of pneumonia compared to systemic hypothermia . Additional technical developments are necessary before selective cooling of the brain can be used as a reliable technique.
Systemic cooling can be obtained by surface cooling, most often with a cooling blanket (Polderman, 2004) or cooling with endovascular catheters (Shlee and Lyden, 2012) . These techniques have the capacity to cool the whole body to the desired temperature within reasonable times. Hypothermia is classified as light or mild (>34ºC), moderate (32-34ºC) or severe (<32ºC). The clinical studies reviewed in this study have used light to moderate hypothermia with a goal temperature of 33 -35 ºC.
The degree of hypothermia is normally determined by the core temperature measured rectally, in esophagus, or in the urinary bladder. Outcome in TBI when using active hypothermia may be related to how long after the accident the cooling was started, the goal temperature, time to reach the goal temperature, and time period of cooling and rewarming (Finkelstein and Alam, 2010) . For example, the negative effects of rewarming-i.e. the rebound increase in ICP during the rewarming and postcooling phase-may overshadow the neuroprotective effects of cooling. Alternative protocols with a shorter time delay before the start of cooling after the accident, a more long-term cooling period, or an extended rewarming phase and better control of ICP and CPP etc., might strengthen the beneficial effects of hypothermia (McIntyre et al., 2003) .
Evaluation of outcome
Most studies used mortality and the five-category assessment Glasgow Outcome Scale (GOS) to evaluate outcome: 1, death; 2, vegetative state; 3, severe disability; 4, moderate disability and 5, good recovery. A GOS score of 4-5 is considered as a favorable/good neurological outcome, while a GOS score of 1-3 is unfavorable/poor outcome (Jennet et al., 1981) .
The Pediatric Cerebral Performance Category (PCPC) scale was used in 3 of the 5 pediatric trials. PCPC is a six-point scale: 1, normal performance; 2, mild disability; 3, moderate disability; 4, severe disability; 5, persistent vegetative state; and 6, death (Biswas et al., 2002; Hutchison et al., 2008) .
Cooling duration and rewarming
Most studies used a cooling period in the 24-to 48-h range, while some studies have used a cooling period longer than 48 h. One reason for using more long-term cooling is that cerebral swelling and edema often are greatest 3-5 days after injury (Fox et al., 2010) . If hypothermia is discontinued at an earlier stage, the injury mechanisms may continue to progress with a greater risk of rebound increase in ICP (Schwab et al., 2001) . A study by Jiang et al. , who compared the effects of long-term cooling with short-term cooling in adults, indicated that longer duration was beneficial .
Cooling generally results in a decrease in ICP, both in adults and in children (Finkelstein and Alam, 2010; Adelson et al., 2005) . Only one study has shown an increase in ICP by cooling (Clifton et al., 2011) . As mentioned above, the recently started Eurotherm3235Trial (Andrews et al., 2013) is based on the hypothesis that the ICP-reducing effect of hypothermia is favorable.
A rebound increase in ICP during the rewarming period has been more common in studies 12 12 using short-term cooling. A more slow and well-controlled rewarming (Povlishock and Wei, 2009 ) and better control of ICP, blood pressure and CPP may reduce the adverse rebound effect of the rewarming phase.
Adverse effects of hypothermia
Even though induced cooling is neuroprotective and improves outcome after a general brain hypoxia as described in the Introduction, the situation may be different after TBI. Cerebral circulation is relatively normal or may even be above normal following resuscitation after general hypoxia, while the brain suffers from compromised circulation with hypoxia in limited areas in and around contusions after a more focal injury, such as after a TBI.
Shivering, increased stress, and increased sympathetic discharge and catecholamine release, are well-known effects of hypothermia with the physiological aim of resetting body temperature towards the values set in the biological thermostat of the brain. The hypothermia-induced reduction in metabolic rate will therefore be counteracted by a simultaneous stress-induced increase in metabolism (Badjatia et al., 2008) . The latter may compromise brain microcirculation increase in release of catecholamines, which may aggravate hypoxia especially in areas in which the perfusion is already significantly reduced. Oddo et al. showed that cooling-induced shivering can cause a significant reduction in brain oxygenation with an increased risk of brain hypoxia (Oddo et al., 2010) . These authors warned against the use of active hypothermia as prophylactic neuroprotectant in the early phase of TBI (Urbano and Oddo, 2008; Oddo et al., 2010) . Shivering can be reduced pharmacologically, e.g by neuromuscular blocking agents, but this therapy has well known side effects i.e. in terms of increased risk of pulmonary emboli, and the increased sympathetic discharge is maintained.
Hypothermia is also associated with hypotension, pulmonary infections, thrombocytopenia, 13 13 hypokalemia, and increased risk of bleedings due to general coagulation disturbances (Finkelstein and Alam, 2010; Rundgren and Engström, 2008) . Hypothermia may also trigger a reduction in plasma volume (Hammersborg et al., 2005) . It may also be clinical relevant that hypothermia reduces and rewarming increases the elimination rate of drugs (Empey et al., 2013) . Noradrenalin given to compensate for hypothermia-induced hypotension may be beneficial by preserving CPP, but it may also induce pulmonary complications (Contant et al., 2001 ) and compromised cerebral circulation.
Trials included and outcome
We found 19 original articles that met the inclusion criteria, 14 of which included all ages or adult patients only, and 5 were pediatric. The characteristics of the trials are given in Table 1 .
Information about mortality and neurological outcome, complications and ICP is presented in Table 2 .
The studies by Clifton et al. from 2001 and can be classified as high-quality studies involving 392 and 97 patients, respectively. There were no significant difference in mortality between the hypothermia group and the normothermia group in these studies. However, the study from 2001 showed more frequent episodes of hypotension and low CPP with hypothermia therapy and there was a longer hospital stay for patients in the hypothermia group in that study. In the study from 2011, noradrenalin was more commonly used to prevent hypotension. In spite of this and that the patients were younger in the hypothermia group, outcome was not better in the hypothermia group in that study. This study also showed a tendency of poorer outcome in patients with diffuse brain injury treated with hypothermia compared to the control group, but there was better outcome with hypothermia in the subgroup of patients who underwent surgical removal of intracranial hematomas. The study by Harris et al. from 2009 included 12 and 13 patients in the hypothermia and normothermia group, respectively. These authors investigated the effect of local hypothermia with a cooling cap, but they had difficulty in reaching the target temperature of 33°C for all patients. They did not find any difference in GOS or in complications between the groups.
Four of the studies in adult patients (Polderman et al., 2002; Liu et al., 2006; Zhi et al., 2003; Inamasu et al., 2006) improved favorable neurological outcome with hypothermia, but no effect on mortality. The study by Zhao et al. had 40 patients in the hypothermia group and 41 patients in the normothermia group. Three months after treatment, more patients had favorable outcome in the hypothermia group (p < 0.04). The study by Qui et al. had 45 patients in each group. At 6 months after TBI, there was no difference in mortality between the groups, but there were more patients with favorable outcome in the hypothermia group. The study by Lee et al. was randomized, and involved 3 groups with patients with a GCS score of between 4 and 8. In group 1 (n = 16), the treatment was guided by ICP/CPP. In group 2 (n = 15), the treatment was also ICP/CPP-guided, but included moderate hypothermia (33-35 ºC) as well. Group 3 (n = 14)
was guided by measurement of brain tissue oxygen and included the same moderate hypothermia. Mortality was low in all groups, and did not differ between the groups. In another study by Qiu et al. (Qiu et al., 2007 ) the effect of hypothermia was analyzed in patients after craniotomy, with a hypothermic group and a normothermic group with 40 patients in each. In this randomized study, mortality was lower and favorable neurological outcome was better in the hypothermia group. In a study by Yan et al. from 2010 the patients were divided in 3 groups according to GCS score (GCS 7-8, 5-6 and 3-4) and improved outcome was shown only in the group with GCS score 7-8. In a study by Gal et al. from 2002 with 15 patients per group, there was a tendency of better outcome in the hypothermia group. A recent large retrospective multicentre study from Japan based on data from the Japan Neurotrauma Data Bank including 401 patients showed a tendency of higher mortality, but better favorable neurological outcome in surviving patients in the hypothermia group. The study can be criticized, however, as the patients in the hypothermia group were significantly younger and inclusion criteria, such as age and method of temperature management, differed between the institutions (Suehiro et al., 2013) .
Three of the 5 pediatric studies analyzed reported that patients treated with hypothermia were slightly more prone to dye (Biswas et al., 2002; Hutchison et al., 2008; Adelson et al., 2013 ) and 2 showed no clear effect on mortality and neurological outcome by hypothermia Adelson et al., 2005) . The study by Biswas et al. from 2002 included only 21 patients, and the authors stated that no conclusion could be drawn from their study regarding outcome.
Special attention should be paid to the higher mortality rate with hypothermia in the A recent review summarized that there is no support today for the use of hypothermia in the treatment of children with TBI (Bhalla et al., 2012) . This conclusion on therapeutic hypothermia agrees with that from a Cochrane analysis from 2009 for both adults and children (Sydenham et al., 2009) . They found 23 trials with acceptable entry criteria, but only 8 fulfilled the required level of quality and in these 8 studies the patients treated with hypothermia were slightly more prone to die.
GCS at admission
Some studies in this review found that severity of brain injury (GCS score) at admission influenced the therapeutic effect of hypothermia, while others did not. Subgroup analysis in four studies found that hypothermia had no benefit in patients with GCS 3-4 (Polderman et al., 2002; Gal et al., 2002; Inmasu et al., 2006; Yan et al., 2010) . It may be that patients with GCS 3-4 are so severely injured that they are unable to benefit from hypothermia. If so, trials including a study population with a low mean GCS are more unlikely to show beneficial effects of hypothermia. However, Liu et al. (2006) and Qiu et al. (2007) 
Intracranial lesion and neurosurgery
A subgroup analysis from the study by Clifton and colleagues (Clifton et al., 2011) showed that patients who underwent surgical removal of intracranial hematomas showed beneficial effects by hypothermia. This hypothesis was supported by other studies included in this review (Polderman et al., 2002; Liu et al.; Inamasu et al., 2006; Qiu et al., 2007; Lee et al., 18 18 2010, Gal et al., 2002) . Neurosurgery and type of brain injury are closely linked as hematomas are surgically removed, whereas patients with diffuse brain injury are exposed to surgery to a less extent.
Intracranial pressure
All 14 studies on adults, except the one by Clifton et al. from 2011, found lower ICP values in the hypothermia group than in the control group. Clifton et al. showed that episodes of raised ICP were significantly more frequent in the hypothermia group than in the normothermia group.
A goal-directed therapy on ICP by hypothermia was used in two adult studies, both indicating positive effects (Polderman et al., 2002; Zhi et al., 2003) . In these studies, the management was (Roberts and Sydenham, 2012) . Thus, to what extent the lower ICP induced by hypothermia affects outcome is still unclear. The newly started Eurotherm3235 hypothermia trial specifically evaluating the effect of ICP on outcome 2013) , will be a welcome contribution.
Four of the pediatric studies reported ICP (Biswas et al., 2002; Adelson et al., 2005; Hutchison et al., 2008; . Li et al. It is difficult to draw any general conclusion from the studies analyzed in this review regarding correlation between ICP, rewarming rate, rebound increase in ICP, and outcome.
Complications
Ten of the 14 studies in adults had data on complications, which can be referred to hypothermia. The type of complications included coagulopathy, cardiovascular complications, and pneumonia Liu et al., 2006; Qiu et al., 2007) (Sydenham et al., 2009) .
No difference in complications between hypothermia and normothermia was reported in four of the five pediatric studies (Biswas et al., 2002; Hutchison et al., 2008; Adelson et al., 2005 and 2013) . One of the pediatric studies (Adelson et al., 2005) found a trend of increased arrhythmias in the hypothermia group.
Limitations
Like most clinical studies, the hypothermia studies analyzed in this review had limitations and the generalizability of the data is limited. Several authors did not report if the difference in outcome between groups was significant or not, and the numbers of patients were small in several studies. 
Summary
The studies included showed conflicting results regarding mortality and neurological outcome and varied in quality. Several trials showed improved neurological outcome with hypothermia and a trend of lower mortality rates, but the best-performed studies showed no difference in outcome or even a tendency of worse outcome, especially in the pediatric population. Adverse effects of hypothermia in TBI patients, such as pneumonia, coagulation disturbances, rebound increase in ICP, and stress-induced compromised circulation of hypoxic areas, may counteract its neuroprotective effects. We conclude that we still lack scientific support for the use of therapeutic hypothermia in TBI patients both for adults and children.
